The aim of this review is, therefore, to evaluate whether the pathological effects of CD44-induced metastasis, epithelial-to-mesenchymal transition (EMT), and chemoresistance within cervical cancer patients can be blunted by immune checkpoint inhibition therapy. The gene discussed is CD44; the disease is cervical cancer.